06/12/2025 | Press release | Distributed by Public on 06/12/2025 14:20
Item 5.07 Submission of matters to a vote of security holders.
ALX Oncology Holdings Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 11, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of Two Class II Directors
Name of Director |
For |
Withheld |
Broker Non-Votes |
|||
Scott Garland |
23,602,975 |
8,662,965 |
11,796,795 |
|||
Barbara Klencke, M.D. |
30,835,565 |
1,430,375 |
11,796,795 |
Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Advisory Vote on the Compensation of the Company's Named Executive Officers
For |
Against |
Abstain |
Broker Non-Votes |
|||
22,147,884 |
8,736,683 |
1,381,373 |
11,796,795 |
The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.
Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm
For |
Against |
Abstain |
||
41,776,769 |
59,969 |
2,225,997 |
The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
1